3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on ...

The open-label, randomized, Phase 2 study will enroll approximately 50 patients with metastatic NSCLC whose tumors express PD-L1 and who have not previously received immune checkpoint inhibitors ...

SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

Texas Instruments (TI) reported robust first-quarter earnings for 2025, buoyed by a steady recovery across key application sectors, particularly in the automotive market. As the global ...

Pfizer’s phase 3 trial assessed the effect of giving a PD-1 inhibitor, sasanlimab, in combination with BCG as a first-line treatment.

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at ...

The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non ...

The study was a randomized, double-blind, placebo-controlled, phase I clinical trial in 20 individuals with idiopathic PD fulfilling the criteria set by the Movement Disorders Society (MDS).